Renale Denervierung und Hypertonie

详细信息    查看全文

• 作者：Prof. Dr. H. Haller (1)
  J. Menne (1)
  F. Limbourg (1)
  B.M. Schmidt (1)
  
• 关键词：Renale Ablation ; Resistenter Hypertonus ; Sympathikus ; Simplicity ; Studie ; Compliance ; Renal nerve ablation ; Resistant hypertension ; Sympathetic nerves ; Simplicity trial ; Compliance
• 刊名：Der Nephrologe
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：9
• 期：5
• 页码：350-356
• 全文大小：436 KB
• 参考文献：1. Kandzari DE, Bhatt DL, Sobotka PA et al (2012) Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol 35:528鈥?35 CrossRef
  2. Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275鈥?281 CrossRef
  3. Krum H, Schlaich MP, Sobotka PA et al (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383:622鈥?29 CrossRef
  4. Symplicity HTN-2 Investigators, Esler MD, Krum H et al (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903鈥?909 CrossRef
  5. Gulati V, White WB (2013) Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens 7:484鈥?93 CrossRef
  6. Bhatt DL, Kandzari DE, O鈥橬eill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393鈥?401 CrossRef
  7. diBona G (2010) Physiology in perspective: the wisdom of the body. Am J Physiol 298:R245鈥揜253
  8. Bernard C (1859) Le莽ons sur les Propri茅t茅s et les Alt茅rations Pathologiques des Liquides de L鈥橭rganisme. Bailli茅re et Fils, Paris 2:170鈥?71
  9. Starling EH (1909) The chemical control of the body. Harvey Lectures 1907鈥?908. Lippincott, New York, S聽115鈥?31
  10. Muller J, Barajas L (1972) Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J Ultrastruct Res 41:533鈥?49 CrossRef
  11. Barajas L, Liu L, Powers K (1992) Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol 70:735鈥?49
  12. diBona G, Esler M (2010) Translational medicine. The antihypertensive effect of renal denervation. Am J Physiol 298:R245鈥揜253
  13. Cowley AW (1992) Long term control of arterial blood pressure. Physiol Rev 72:231鈥?00
  14. Campese VM, Kogosov E (1995) Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878鈥?82 CrossRef
  15. Kopp UC, Jones SY, DiBona GF (2008) Afferent renal denervation impairs baroreflex control of efferent renal sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 295:R1882鈥揜1890
  16. Esler M, Jennings G, Korner P et al (1988) The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11:3鈥?0 CrossRef
  17. Grassi G, Colombo M, Seravalle G et al (1998) Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 31:64鈥?7 CrossRef
  18. Stella A, Zanchetti A (1991) Functional role of renal afferents. Physiol Rev 71:659鈥?82
  19. Smithwick RH, Bush RD, Kinsey D, Whitelaw GP (1956) Hypertension and associated cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy. J Am Med Assoc 160:1023鈥?026 CrossRef
  20. Schlaich MP, Sobotka PA, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932鈥?34 CrossRef
  21. Brinkmann J, Heusser K, Schmidt BM et al (2012) Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 60:1485鈥?490 CrossRef
  22. Fadl Elmula FE, Hoffmann P, Fossum E et al (2013) Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 62:526鈥?32 CrossRef
  23. Fadl Elmula FE, Hoffmann P, Larstorp AC et al (2014) Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63:991鈥?99 CrossRef
  24. Luft FC (2014) SIMPLICITY: not all that simple. Kidney Int 85:999鈥?001 CrossRef
  25. Witkowski A, Prejbisz A, Florczak E et al (2011) Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58:559鈥?65 CrossRef
  26. Linz D, Mahfoud F, Schotten U et al (2012) Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 60:172鈥?78 CrossRef
  27. Mahfoud F, Cremers B, Janker J et al (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60:419鈥?24 CrossRef
  28. Hering D, Mahfoud F, Walton AS et al (2012) Renal denervation in moderate to severe CKD. J Am Soc Nephrol 23:1250鈥?257 CrossRef
  29. Brandt MC, Hoppe UC, Vonend O et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940鈥?946 CrossRef
  30. Brandt MC, Mahfoud F, Reda S et al (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901鈥?09 CrossRef
  31. Ott C, Janka R, Schmid A et al (2013) Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol 8:1195鈥?201 CrossRef
  
• 作者单位：Prof. Dr. H. Haller (1)
  J. Menne (1)
  F. Limbourg (1)
  B.M. Schmidt (1)
  
  1. Klinik f眉r Nieren- und Hochdruckkrankheiten, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
  
• ISSN：1862-0418

文摘

Catheter-based renal nerve ablation can lower blood pressure (BP) in hypertensive patients. The concept is based on solid physiological studies suggesting that efferent and afferent renal nerves contribute to arterial hypertension. The preliminary results on the efficacy and safety of catheter-based renal nerve ablation on BP control in resistant hypertension have been encouraging; however, these studies were uncontrolled. In several small studies it was observed early that most patients can be controlled by pharmaceutical treatment and only a few patients respond to ablation therapy. A large prospective trial with a control group (sham treatment) was therefore necessary. The Simplicity-3 trial fulfilled these criteria. More than 600 patients were successfully studied and in March 2014 the results were published. No significant differences between the two groups were observed, one treated with renal nerve ablation and the other group controlled only by medication. These results are in contrast to the previous (uncontrolled) studies and observations from a worldwide registry. Several explanations have been put forward to explain these results. Important are (1) compliance, i.e. patients taking their medication during the study and also (2) inexperience with the method in small centers. Simplicity-3 has put a halt on using renal denervation in most countries. It is now important to find out why the method only works in some patients, what the criteria to use it are and to define a patient group where renal denervation is useful as a therapeutic method to treat patients with hypertension.